United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2023 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 10/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease PR Newswire

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The dividend is payable June 12, 2026 to stockholders of.

Agree Realty Declares Monthly Common and Preferred Dividends

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis.

InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solution.

Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 on track to initiate in second half of 2026 Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China CR-002, a PD-L1-targeted ADC, on track to enter the clinic in second half of 2026 Multiple key clinical data readouts anticipated beginning in Q1 2027 WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights.

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

The 10-year Treasury yield sits at 4.26% and the Fed funds rate has been held at 3.75% for more than four months.

This Portfolio Pays Me Every Month (No Work Needed)

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended March 31, 2026. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. First Quarter 2026 Financial and Operating Highlights: Invested approximately $424 million in 100 retail net lease properties 15 development or Developer Funding Platform ("DFP") projects completed or under construction with anticipated total cos.

Agree Realty Corporation Reports First Quarter 2026 Results

Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the latest preclinical data for three proprietary pipeline assets at the American Association for Cancer Research (AACR) Annual Meeting (from April 17 to 22), including CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC). CStone's Proprietary ADC Technology Platform All three antibody-drug conjugates (ADCs) presented at AACR – CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC) – are developed utilizing CStone's proprietary ADC technology platform, which incorporates the following core features: High Stability & Precise Payload Release: The platform utilizes CStone's proprietary CSL20 linker, a hydrophilic construct designed for enhanced stability in circulation.

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across various cancer models at low single ‑ digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC) Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 MORRISTOWN, N.J., April 19, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA.

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Passive income is revenue generated without the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

Boomers and Gen X Love Passive Income From 5 of the Safest Monthly Dividend Stocks

Ingelheim, Germany  and  Shanghai , China /Cambridge, Mass.  –  15 April ,  202 6   – Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim's DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab's DLL3-targeting ADC. The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC); diseases where patients urgently need more effective treatment options.

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

INCHEON, Korea--(BUSINESS WIRE)-- #ADC--Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis's first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1 The Phase 1 clinical trial for SBE303 is an open‑label, multi-center, first‑in‑human trial to evaluate the safety, tolerability an.

Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share, representing a 1.9% month-over-month increase. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The divid.

Agree Realty Declares Increased Monthly Common Dividend

Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

Shares of Agree Realty Corporation (NYSE: ADC - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating

Agree Realty Corporation (NYSE:ADC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

ADC Therapeutics Announces New Employee Inducement Grant

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its first quarter 2026 operating results after the market closes on Tuesday, April 21, 2026. A conference call to discuss the Company's operating results is scheduled for Wednesday, April 22, 2026, at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871   International (646) 307-196.

Agree Realty Announces First Quarter 2026 Earnings Release Date and Conference Call Information

Exchange Traded Concepts LLC lessened its stake in shares of Agree Realty Corporation (NYSE: ADC) by 45.2% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,704 shares of the real estate investment trust's stock after selling 38,465 shares during the period. Exchange Traded Concepts

Exchange Traded Concepts LLC Has $3.36 Million Stock Position in Agree Realty Corporation $ADC

While many Baby Boomers have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.

Retirees Trust Our 5 Favorite Strong Buy Safe Monthly Pay High-Yield Dividend Stocks

HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC. The studies will evaluate these two novel ADC candidates in combination with the Company's pioneering immuno-oncology (IO) 2.0 bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), as well as other proprietary high-potential anti-tumor assets, including AK117 (anti-CD47 monoclonal antibody) and AK109 (anti-VEGF monoclonal antibody), across a spectrum of advanced solid tumors.

Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company's internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (A.

Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)

MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it will present three preclinical abstracts, including an oral minisymposium and two posters, highlighting its next-generation antibody-drug conjugate (ADC) portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Brevan Howard Capital Management LP grew its stake in shares of Agree Realty Corporation (NYSE: ADC) by 21.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,932 shares of the real estate investment trust's stock after purchasing an additional 8,481 shares during

Brevan Howard Capital Management LP Acquires 8,481 Shares of Agree Realty Corporation $ADC

Bamco Inc. NY increased its position in shares of Agree Realty Corporation (NYSE: ADC) by 14.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 74,128 shares of the real estate investment trust's stock after acquiring an additional

Agree Realty Corporation $ADC Holdings Lifted by Bamco Inc. NY

- Confirmed response rates in expansion cohorts of  32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif.

CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

Engineers Gate Manager LP bought 1,144,617 Agree Realty (ADC) shares Quarter-end position value rose by $82.48 million, reflecting both the share increase and stock price changes This trade represented 0.99% of the fund's 13F reportable assets under management Fund held 1,182,229 ADC shares worth $85.16 million at quarter end The ADC stake now accounts for 1.01% of 13F AUM, which places it outside the fund's top five holdings

Engineers Gate Builds $85 Million Position in Net-Lease Retail REIT Agree Realty

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE SECOND QUARTER OF 2025. THE DIVIDEND IS PAYABLE JUNE 12, 2026 TO STOCKHOLDERS OF.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

PATENT REINFORCES STRATEGIC FOUNDATION FOR LEAD ADC AKTX-101 AND EXPANDING ADC PIPELINE TO NEW MOLECULES TARGETING HIGH-VALUE ONCOLOGY INDICATIONS PATENT REINFORCES STRATEGIC FOUNDATION FOR LEAD ADC AKTX-101 AND EXPANDING ADC PIPELINE TO NEW MOLECULES TARGETING HIGH-VALUE ONCOLOGY INDICATIONS

AKARI THERAPEUTICS SECURES KEY EUROPEAN PATENT FOR ITS NOVEL RNA SPLICING MODULATOR ADC PAYLOAD, STRENGTHENING GLOBAL IP ESTATE FOR ALL MAJOR GLOBAL MARKETS

BEIJING, MAY 06, 2026 (GLOBE NEWSWIRE) -- INNOCARE PHARMA (HKEX: 9969; SSE: 688428), A LEADING BIOPHARMACEUTICAL COMPANY FOCUSING ON THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES, ANNOUNCED TODAY THAT THE CENTER FOR DRUG EVALUATION (CDE) OF THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS APPROVED THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO INITIATE A CLINICAL TRIAL OF ITS NOVEL CDH17 TARGETED ADC, ICP-B208. CDH17 IS A CALCIUM-DEPENDENT CELL ADHESION PROTEIN THAT PLAYS A KEY ROLE IN TUMOR CELL PROLIFERATION, MIGRATION, AND METASTASIS.

INNOCARE ANNOUNCES APPROVAL OF CLINICAL TRIAL OF NOVEL CDH7 TARGETED ADC ICP-B208 IN CHINA

PARIS--(BUSINESS WIRE)--WAIV, FORMERLY OWKIN DX, A PARIS-BASED COMPANY CATALYZING AI PRECISION TESTING, TODAY ANNOUNCED IT HAS ENTERED A COLLABORATION WITH DAIICHI SANKYO (TSE: 4568) TO LEAD DIGITAL PATHOLOGY BIOMARKER DISCOVERY FOR AN ANTIBODY-DRUG CONJUGATE (ADC) PROGRAM. WITH DEEP EXPERTISE ACROSS DIVERSE PATHOLOGY AND MULTIMODAL DATA, AND A GLOBAL DATA NETWORK SPANNING ACADEMIC INSTITUTIONS, HOSPITALS, AND LABORATORIES, WAIV HAS A PROVEN TRACK RECORD DELIVERING AI-POWERED BIOMARKER SOLUTION.

WAIV ENTERS COLLABORATION WITH DAIICHI SANKYO TO DELIVER AI-DERIVED BIOMARKERS FOR ADC PROGRAM

LOTIS-5 PHASE 3 TOPLINE DATA EXPECTED IN SECOND QUARTER 2026, WITH FULL DATA FOR LOTIS-5 AND LOTIS-7 ANTICIPATED BY YEAR END FIRST QUARTER 2026 NET PRODUCT REVENUE OF $20.0 MILLION CASH AND CASH EQUIVALENTS OF $231.0 MILLION AS OF MARCH 31, 2026, WITH AN EXPECTED CASH RUNWAY AT LEAST INTO 2028 COMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. EDT LAUSANNE, SWITZERLAND, MAY 4, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED RECENT OPERATIONAL UPDATES.

ADC THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES

LAUSANNE, SWITZERLAND, MAY 1, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 49,400 OF THE COMPANY'S COMMON SHARES TO TWO NEW EMPLOYEES ON MAY 1, 2026 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANTS TO NEW EMPLOYEES UNDER INDUCEMENT PLAN

ASCEND PHASE 1/2 GLOBAL CLINICAL TRIAL ONGOING, EVALUATING CR-001, A PD-1 X VEGF BISPECIFIC ANTIBODY, IN MULTIPLE SOLID TUMOR TYPES IN FIRST-LINE AND PREVIOUSLY TREATED PATIENTS; FIRST ADC COMBINATION TRIAL WITH CR-001 ON TRACK TO INITIATE IN SECOND HALF OF 2026 PHASE 1/2 TRIAL OF CR-003, AN ITGB6-TARGETED ADC, ONGOING IN CHINA CR-002, A PD-L1-TARGETED ADC, ON TRACK TO ENTER THE CLINIC IN SECOND HALF OF 2026 MULTIPLE KEY CLINICAL DATA READOUTS ANTICIPATED BEGINNING IN Q1 2027 WALTHAM, MASS., APRIL 29, 2026 (GLOBE NEWSWIRE) -- CRESCENT BIOPHARMA, INC. (CRESCENT OR THE COMPANY) (NASDAQ: CBIO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO RAPIDLY ADVANCING THE NEXT WAVE OF THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026 AND RECENT BUSINESS HIGHLIGHTS.

CRESCENT BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

LAUSANNE, SWITZERLAND, APRIL 27, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST ON MONDAY, MAY 4, 2026, AT 8:30 A.M. EDT TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND PROVIDE OPERATIONAL UPDATES.

ADC THERAPEUTICS TO HOST FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL ON MAY 4, 2026

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED MARCH 31, 2026. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. FIRST QUARTER 2026 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $424 MILLION IN 100 RETAIL NET LEASE PROPERTIES 15 DEVELOPMENT OR DEVELOPER FUNDING PLATFORM ("DFP") PROJECTS COMPLETED OR UNDER CONSTRUCTION WITH ANTICIPATED TOTAL COS.

AGREE REALTY CORPORATION REPORTS FIRST QUARTER 2026 RESULTS

RESULTS FROM EARLY CLINICAL STUDIES ACROSS JUNSHI BIOSCIENCES' INNOVATIVE PIPELINE WERE PRESENTED AT THE 2026 AACR, FEATURING: JS212 (EGFR/HER3 ADC), THE J

JUNSHI BIOSCIENCES PRESENTS RESULTS FROM JS207 (PD-1/VEGF BSAB) PHASE 2 COMBO STUDIES AND JS212 (EGFR/HER3 ADC) FIH PHASE 1/2 STUDY AT AACR 2026

SUZHOU, CHINA, APRIL 19, 2026 /PRNEWSWIRE/ -- CSTONE PHARMACEUTICALS ("CSTONE," HKEX: 2616), AN INNOVATION-DRIVEN BIOPHARMACEUTICAL COMPANY FOCUSED ON THE RESEARCH AND DEVELOPMENT OF THERAPIES FOR ONCOLOGY, IMMUNOLOGY, INFLAMMATION, AND OTHER KEY DISEASE AREAS, TODAY ANNOUNCED THAT THE COMPANY PRESENTED THE LATEST PRECLINICAL DATA FOR THREE PROPRIETARY PIPELINE ASSETS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING (FROM APRIL 17 TO 22), INCLUDING CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), AND CS5008 (DLL3/SSTR2 ADC). CSTONE'S PROPRIETARY ADC TECHNOLOGY PLATFORM ALL THREE ANTIBODY-DRUG CONJUGATES (ADCS) PRESENTED AT AACR  CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), AND CS5008 (DLL3/SSTR2 ADC)  ARE DEVELOPED UTILIZING CSTONE'S PROPRIETARY ADC TECHNOLOGY PLATFORM, WHICH INCORPORATES THE FOLLOWING CORE FEATURES: HIGH STABILITY & PRECISE PAYLOAD RELEASE: THE PLATFORM UTILIZES CSTONE'S PROPRIETARY CSL20 LINKER, A HYDROPHILIC CONSTRUCT DESIGNED FOR ENHANCED STABILITY IN CIRCULATION.

CSTONE PRESENTED PRECLINICAL DATA FOR THREE NOVEL OR DIFFERENTIATED ADCS AT AACR 2026, INCLUDING CS5007 (EGFR/HER3)

DATA DEMONSTRATE PRECLINICAL PROOF-OF-CONCEPT FOR HWK-007, HWK-016 AND HWK-206, UNDERPINNED BY WHITEHAWK'S PROPRIETARY CARBON BRIDGE CYSTEINE RE-PAIRING PLATFORM TUMOR REGRESSIONS OBSERVED ACROSS VARIOUS CANCER MODELS AT LOW SINGLE  DIGIT MG/KG DOSES, WITH FAVORABLE TOLERABILITY (HNSTD 60 MG/KG) AND LOW SYSTEMIC LEVELS OF FREE PAYLOAD (0.01% AUC) PHASE 1 TRIALS FOR HWK-007 AND HWK-016 ARE ONGOING; AN IND SUBMISSION FOR HWK-206 IS ON TRACK FOR MID-2026 MORRISTOWN, N.J., APRIL 19, 2026 /PRNEWSWIRE/ -- WHITEHAWK THERAPEUTICS, INC.(NASDAQ: WHWK), A CLINICAL-STAGE ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DELIVER IMPROVED ANTIBODY DRUG CONJUGATE (ADC)CANCER TREATMENTS, TODAY ANNOUNCED THE PRESENTATION OF NEW PRECLINICAL DATA ACROSS ITS ADC PORTFOLIO AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026, TAKING PLACE APRIL 17-22, 2026, IN SAN DIEGO, CA.

WHITEHAWK THERAPEUTICS PRESENTS COMPREHENSIVE PRECLINICAL DATA HIGHLIGHTING ITS NEXT-GENERATION ADC PORTFOLIO AT THE AACR 2026

ONVANSERTIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN DEMONSTRATED ENHANCED ANTITUMOR ACTIVITY, INCLUDING TUMOR REGRESSION AND APOPTOSIS IN HER2-LOW BREAST CANCER MODELS, SUPPORTING ITS POTENTIAL FOR PATIENTS WITH LIMITED TREATMENT OPTIONS ONVANSERTIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN DEMONSTRATED ENHANCED ANTITUMOR ACTIVITY, INCLUDING TUMOR REGRESSION AND APOPTOSIS IN HER2-LOW BREAST CANCER MODELS, SUPPORTING ITS POTENTIAL FOR PATIENTS WITH LIMITED TREATMENT OPTIONS

CARDIFF ONCOLOGY PRESENTS PRECLINICAL DATA ON ITS PLK1 INHIBITOR ONVANSERTIB IN COMBINATION WITH A HER2-TARGETED ADC AT THE 2026 AACR ANNUAL MEETING

INGELHEIM, GERMANY AND SHANGHAI , CHINA /CAMBRIDGE, MASS.  15 APRIL , 202 6  BOEHRINGER INGELHEIM AND ZAI LAB(NASDAQ: ZLAB; HKEX: 9688)TODAY ANNOUNCED A CLINICALCOLLABORATIONFOCUSED ONPIONEERINGADUALDLL3-TARGETINGCOMBINATION.THE PHASEIB/II STUDY WILL ASSESS THE SAFETY, TOLERABILITY, AND INITIAL CLINICAL ACTIVITY OF COMBININGOBRIXTAMIG, BOEHRINGER INGELHEIM'S DLL3/CD3T-CELLENGAGER, WITHZOCILURTATUGPELITECAN(ZOCI;FORMERLYZL1310), ZAILAB'SDLL3-TARGETINGADC.THE STUDYWILL ENROLLPATIENTS WITH POORLY DIFFERENTIATED NECS AND EXTENSIVE STAGE SCLC (ES-SCLC);DISEASESWHERE PATIENTS URGENTLY NEED MORE EFFECTIVE TREATMENTOPTIONS.

BOEHRINGER INGELHEIM AND ZAI LAB ANNOUNCE COLLABORATION ON DLL3TARGETING TCELL ENGAGER AND ADC COMBINATION IN SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CARCINOMAS

INCHEON, KOREA--(BUSINESS WIRE)-- #ADC--SAMSUNG BIOEPIS CO., LTD. ANNOUNCED TODAY THE INITIATION OF PHASE 1 CLINICAL TRIAL FOR SBE303. SBE303 IS SAMSUNG BIOEPIS'S FIRST NOVEL ANTIBODY-DRUG CONJUGATE (ADC) CANDIDATE ENGINEERED TO BIND TO NECTIN-4, AN ADHESION PROTEIN THAT IS SPECIFICALLY EXPRESSED IN TUMOR CELLS, INCLUDING UROTHELIAL CANCER, LUNG CANCER, AND BREAST CANCER.1 THE PHASE 1 CLINICAL TRIAL FOR SBE303 IS AN OPENLABEL, MULTI-CENTER, FIRSTINHUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AN.

SAMSUNG BIOEPIS INITIATES PHASE 1 CLINICAL TRIAL FOR SBE303, NECTIN-4 TARGETING ANTIBODY-DRUG CONJUGATE (ADC) CANDIDATE

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE, REPRESENTING A 1.9% MONTH-OVER-MONTH INCREASE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE SECOND QUARTER OF 2025. THE DIVID.

AGREE REALTY DECLARES INCREASED MONTHLY COMMON DIVIDEND

STRATEGIC PARTNERSHIP ENABLES AKARI TO ACCELERATE IND FILING BY LATE 2026 STRATEGIC PARTNERSHIP ENABLES AKARI TO ACCELERATE IND FILING BY LATE 2026

AKARI THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH WUXI XDC TO ADVANCE DEVELOPMENT OF ITS NOVEL ADC PAYLOAD TARGETING RNA SPLICING

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS FIRST QUARTER 2026 OPERATING RESULTS AFTER THE MARKET CLOSES ON TUESDAY, APRIL 21, 2026. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR WEDNESDAY, APRIL 22, 2026, AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (800) 715-9871  INTERNATIONAL (646) 307-196.

AGREE REALTY ANNOUNCES FIRST QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

LAUSANNE, SWITZERLAND, APRIL 1, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE A GRANT OF OPTIONS TO PURCHASE AN AGGREGATE OF 17,000 OF THE COMPANY'S COMMON SHARES TO A NEW EMPLOYEE ON APRIL 1, 2026 ("GRANT"). THE GRANT WAS OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEE'S EMPLOYMENT.

ADC THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANT

HONG KONG, MARCH 24, 2026 /PRNEWSWIRE/ --AKESO, INC. (9926.HK) ("AKESO" OR THE "COMPANY") ANNOUNCED TODAY THAT IT HAS RECEIVED CLEARANCE FROM THE CENTER FOR DRUG EVALUATION (CDE) OF CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) TO INITIATE PHASE II CLINICAL TRIALS FOR AK146D1, A FIRST-IN-CLASS TROP2 /NECTIN4 BISPECIFIC ANTIBODY-DRUG CONJUGATE (ADC), AND AK138D1, AN INNOVATIVE HER3-TARGETING ADC. THE STUDIES WILL EVALUATE THESE TWO NOVEL ADC CANDIDATES IN COMBINATION WITH THE COMPANY'S PIONEERING IMMUNO-ONCOLOGY (IO) 2.0 BISPECIFIC ANTIBODIES, CADONILIMAB (PD-1/CTLA-4) AND IVONESCIMAB (PD-1/VEGF), AS WELL AS OTHER PROPRIETARY HIGH-POTENTIAL ANTI-TUMOR ASSETS, INCLUDING AK117 (ANTI-CD47 MONOCLONAL ANTIBODY) AND AK109 (ANTI-VEGF MONOCLONAL ANTIBODY), ACROSS A SPECTRUM OF ADVANCED SOLID TUMORS.

AKESO ADVANCES "IO 2.0 + ADC 2.0" STRATEGY WITH PHASE II INITIATION OF NOVEL ADCS COMBINED WITH IVONESCIMAB AND CADONILIMAB

ADCS ARE A MAJOR NEW MARKET; COMPANY DEMONSTRATES ABILITY TO DISCERN ANTIBODY TOXICITY FROM PAYLOAD TOXICITY AND SHOW DIFFERENTIAL LINKER CHEMISTRY TOXICITY ADCS ARE A MAJOR NEW MARKET; COMPANY DEMONSTRATES ABILITY TO DISCERN ANTIBODY TOXICITY FROM PAYLOAD TOXICITY AND SHOW DIFFERENTIAL LINKER CHEMISTRY TOXICITY

VIVOSIM RELEASES ANTIBODY DRUG CONJUGATE (ADC) DATA SHOWING POWER TO DETECT ADC TOXICITY AND GUIDE DESIGN OF SAFER ADCS

SHANGHAI & CAMBRIDGE, MASS.--(BUSINESS WIRE)--ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THREE OF THE COMPANY'S INTERNALLY-DEVELOPED INVESTIGATIONAL ONCOLOGY THERAPIES WILL BE PRESENTED ACROSS FOUR POSTER SESSIONS AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026 TAKING PLACE APRIL 17-22 IN SAN DIEGO, CALIFORNIA. THESE NEXT-GENERATION CANDIDATES INCLUDE: ZOCILURTATUG PELITECAN (ZOCI, FORMERLY ZL-1310), A DLL3-TARGETING ANTIBODY-DRUG CONJUGATE (A.

ZAI LAB TO PRESENT NEW DATA ON THREE INTERNALLY DEVELOPED ONCOLOGY CANDIDATES AT AACR 2026, INCLUDING ZOCILURTATUG PELITECAN, A DLL3-TARGETING ANTIBODY-DRUG CONJUGATE (ADC)

MORRISTOWN, N.J., MARCH 17, 2026 /PRNEWSWIRE/ -- WHITEHAWK THERAPEUTICS, INC.(NASDAQ: WHWK), A CLINICAL-STAGE ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DELIVER IMPROVED ANTIBODY DRUG CONJUGATE (ADC)CANCER TREATMENTS, TODAY ANNOUNCED IT WILL PRESENT THREE PRECLINICAL ABSTRACTS, INCLUDING AN ORAL MINISYMPOSIUM AND TWO POSTERS, HIGHLIGHTING ITS NEXT-GENERATION ANTIBODY-DRUG CONJUGATE (ADC) PORTFOLIO AT THEAMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026, TAKING PLACE APRIL 1722, 2026, IN SAN DIEGO, CA.

WHITEHAWK THERAPEUTICS TO HIGHLIGHT ITS NEXT-GENERATION ADC PORTFOLIO AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026

- CONFIRMED RESPONSE RATES IN EXPANSION COHORTS OF 32% AT 10 MG/KG Q3W DOSE AND 20% AT 8.6 MG/KG Q3W - - ESTIMATED PROGRESSION FREE SURVIVAL OF 7.1 MONTHS AT 10 MG/KG AND 6.8 MONTHS AT 8.6 MG/KG - - GRADE 3 DIARRHEA RATE OF 10% IN ONGOING DOSE OPTIMIZATION COHORTS - - FDA INTERACTIONS TARGETED FOR MID-YEAR WITH GOAL TO ALIGN ON POTENTIAL REGISTRATIONAL TRIAL DESIGN IN LATE-LINE COLORECTAL CANCER (CRC) - - PHASE 1 STUDY EVALUATING COMBINATION WITH BEVACIZUMAB INITIATED; PHASE 1B/2 CHEMOTHERAPY COMBINATION STUDY TO BE INITIATED BY THE END OF 2026 - - CONFERENCE CALL ON MONDAY, MARCH 16 AT 8:00 A.M. ET - SOUTH SAN FRANCISCO, CALIF.

CYTOMX'S VARSETATUG MASETECAN (EPCAM PROBODY ADC) CONTINUES TO DEMONSTRATE POSITIVE DATA SUPPORTING POTENTIAL AS A NEW TREATMENT OPTION IN LATE-LINE COLORECTAL CANCER

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC